article 3 months old

Australian Broker Call *Extra* Edition – Jul 11, 2022

Daily Market Reports | Jul 11 2022

This story features AUSTRALIAN CLINICAL LABS LIMITED, and other companies. For more info SHARE ANALYSIS: ACL

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities.

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.

One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.

Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.

Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.

The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.

The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.

COMPANIES DISCUSSED IN THIS ISSUE

Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)

ACL   ADH   AMP   ASX   BCI   CHN (2)   DHG   FFX   FPH   HLS   HUB   HVN   IDX   IFL   JAN   JHG   MFG   MMI   NWL   OKU   PDL   PME   PPT   PTM   REA   RMC   RMD   RSG   SBM   SHL   WAF  

ACL    AUSTRALIAN CLINICAL LABS LIMITED

Healthcare services – Overnight Price: $4.50

Goldman Sachs rates ((ACL)) as Buy (1) –

Goldman Sachs notes recent investment into the applications of AI into radiology mean the technology is approaching commercialisation and revenue generation. 

While the AI algorithms improve efficiency and accuracy of diagnosis, the broker notes the technology can also provide productivity gains that could help mitigate a shortage of radiologists in the near-term.

For Australian Clinical Labs, the broker maintains a Buy rating and target price of $6.50, noting the Buy rating is attributed to factors outside AI. 

This report was published on July 7, 2022.

Target price is $6.50 Current Price is $4.50 Difference: $2
If ACL meets the Goldman Sachs target it will return approximately 44% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY22:

Goldman Sachs forecasts a full year FY22 dividend of 57.40 cents and EPS of 97.30 cents.
At the last closing share price the estimated dividend yield is 12.76%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 4.62.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 23.00 cents and EPS of 40.40 cents.
At the last closing share price the estimated dividend yield is 5.11%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.14.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

ADH    ADAIRS LIMITED

Furniture & Renovation – Overnight Price: $2.30

Jarden rates ((ADH)) as Downgrade to Overweight from Buy (2) –

Jarden updates sales and earnings estimates for Adairs to allow for inflationary pressure on consumers' furniture and homewares spend and operating costs.

The rating is downgraded to Overweight from Buy as the broker anticipates management may lower the FY23 earnings outlook at upcoming FY22 results. The target price drops to $3.21 from $4.74.

Despite these changes, the analyst reminds investors there's value in being patient until largely-macro-driven earnings headwinds subside.

This report was published on July 7, 2022.

Target price is $3.21 Current Price is $2.30 Difference: $0.91
If ADH meets the Jarden target it will return approximately 40% (excluding dividends, fees and charges).
Current consensus price target is $3.50, suggesting upside of 57.0%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Jarden forecasts a full year FY22 EPS of 24.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.47.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 30.4, implying annual growth of -19.4%.
Current consensus DPS estimate is 18.0, implying a prospective dividend yield of 8.1%.
Current consensus EPS estimate suggests the PER is 7.3.

Forecast for FY23:

Jarden forecasts a full year FY23 EPS of 25.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.95.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 33.4, implying annual growth of 9.9%.
Current consensus DPS estimate is 23.3, implying a prospective dividend yield of 10.4%.
Current consensus EPS estimate suggests the PER is 6.7.

Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

AMP    AMP LIMITED

Insurance – Overnight Price: $1.01

Jarden rates ((AMP)) as Neutral (3) –

Jarden has made negative mark to market adjustments across its wealth platforms and asset management coverage, accounting for recent weakness in equity and bonds markets. 

Across wealth managers, the broker highlighted while weaker markets weighted on funds under administration across the sector it does see better value outside of AMP. 

The Neutral rating is retained and the target price decreases to $1.25 from $1.30.

This report was published on July 6, 2022.

Target price is $1.25 Current Price is $1.01 Difference: $0.24
If AMP meets the Jarden target it will return approximately 24% (excluding dividends, fees and charges).
Current consensus price target is $1.12, suggesting upside of 9.6%(ex-dividends)
The company's fiscal year ends in December.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 0.00 cents and EPS of 6.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.03.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 6.5, implying annual growth of N/A.
Current consensus DPS estimate is 0.6, implying a prospective dividend yield of 0.6%.
Current consensus EPS estimate suggests the PER is 15.7.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 5.00 cents and EPS of 8.70 cents.
At the last closing share price the estimated dividend yield is 4.95%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.61.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 8.6, implying annual growth of 32.3%.
Current consensus DPS estimate is 2.4, implying a prospective dividend yield of 2.4%.
Current consensus EPS estimate suggests the PER is 11.9.

Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

ASX    ASX LIMITED

Wealth Management & Investments – Overnight Price: $85.14

Jarden rates ((ASX)) as Underweight (4) –

Jarden leaves its forecasts for the ASX largely unchanged following June ASX statistics that show a recovery in equities trading though the futures trading recovery is proving slower than expected.

The target price falls to $73.10 from $75.35 while the Underweight rating is maintained.

The analyst points out falling equity markets have lowered confidence in IPOs, which experienced the weakest June in over a decade.

This report was published on July 7, 2022.

Target price is $73.10 Current Price is $85.14 Difference: minus $12.04 (current price is over target).
If ASX meets the Jarden target it will return approximately minus 14% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $80.97, suggesting downside of -3.4%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 235.00 cents and EPS of 261.00 cents.
At the last closing share price the estimated dividend yield is 2.76%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 32.62.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 259.3, implying annual growth of 4.4%.
Current consensus DPS estimate is 233.3, implying a prospective dividend yield of 2.8%.
Current consensus EPS estimate suggests the PER is 32.3.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 246.10 cents and EPS of 273.40 cents.
At the last closing share price the estimated dividend yield is 2.89%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 31.14.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 275.4, implying annual growth of 6.2%.
Current consensus DPS estimate is 247.7, implying a prospective dividend yield of 3.0%.
Current consensus EPS estimate suggests the PER is 30.4.

Market Sentiment: -0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

BCI    BCI MINERALS LIMITED

Iron Ore – Overnight Price: $0.24

Bell Potter rates ((BCI)) as Buy (1) –

BCI Minerals is facing development issues with its Mardie salt and potash project as inflation has prompted a review of project design and potential cost saving initiatives, with an update to be provided when sufficiently advanced. 

Expected first salt sales have also been delayed a year to the first half of FY26, a result of construction delays, extreme weather events and mobility restrictions. 

Given the Mardie project remains BCI Minerals' primary development focus, the broker anticipates the company may consider the sale of its Iron Valley earnings stream.

The Buy rating is retained and the target price decreases to $0.53 from $0.61.

This report was published on July 8, 2022.

Target price is $0.53 Current Price is $0.24 Difference: $0.29
If BCI meets the Bell Potter target it will return approximately 121% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 0.00 cents and EPS of 0.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 40.00.

Forecast for FY23:

Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of 1.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.00.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CHN    CHALICE MINING LIMITED

Industrial Metals – Overnight Price: $4.01

Bell Potter rates ((CHN)) as Buy (1) –

Chalice Mining has updated its Gonneville resources to 350Mt from maiden 330Mt estimate moving 70% of the Resource into the Higher Confidence zone, up from 45%.

Grades are broadly unchanged.

The update met Bell Potter's forecasts. 

Speculative Buy rating and $11.10 target price retained.

This report was published on July 11, 2022.

Target price is $11.10 Current Price is $4.01 Difference: $7.09
If CHN meets the Bell Potter target it will return approximately 177% (excluding dividends, fees and charges).

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Bell Potter rates ((CHN)) as Buy (1) –

Drilling at Chalice Mining's Julimar project have revealed early signs of fresh discovery, with visual logging of three wide spaced holes revealing zones of disseminated sulphides between 15-80 metres wide. Bell Potter notes both copper and nickel mineralisation have been confirmed.

The broker notes assays will be required, and these are expected within six weeks, but finds this an exciting development for the company, being the strongest indication of a potential repeat of the Gonneville deposit. 

The Buy rating and target price of $11.10 are retained.

This report was published on July 8, 2022.

Target price is $11.10 Current Price is $4.01 Difference: $7.09
If CHN meets the Bell Potter target it will return approximately 177% (excluding dividends, fees and charges).

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

DHG    DOMAIN HOLDINGS AUSTRALIA LIMITED

Real Estate – Overnight Price: $3.32

Goldman Sachs rates ((DHG)) as Upgrade to Buy from Neutral (1) –

Goldman Sachs examines the medium-term earnings outlook for Australian classifieds post covid, and spies valuation support for property classifeds.

The broker says fundamentals are positive for real-estate classifieds and expects budgets will rise at the expense of commissions and cites general under-monetisation of lead generation.

Goldman Sachs notes a gloomy property outlook is pressuring share prices over earnings but expects declining off-market listings and rental recovery will support listings into the medium term.

Domain Holdings Australia is upgraded to Buy from Neutral, despite risks associated with its depth-on-one portal model, the broker noting strong valuation support (the share prices has fallen -49% since February), a commitment to margin expansion, yield upside, and potential M&A support relating to major shareholder Nine Entertainment ((NEC)).

EPS forecasts fall 03% in FY22 and -3% in FY25. Target price falls to $4.20 from $5.20 in March.

This report was published on July 11, 2022.

Target price is $4.20 Current Price is $3.32 Difference: $0.88
If DHG meets the Goldman Sachs target it will return approximately 27% (excluding dividends, fees and charges).
Current consensus price target is $4.83, suggesting upside of 45.3%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Goldman Sachs forecasts a full year FY22 dividend of 4.00 cents and EPS of 9.80 cents.
At the last closing share price the estimated dividend yield is 1.20%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 33.88.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 9.8, implying annual growth of 67.8%.
Current consensus DPS estimate is 5.8, implying a prospective dividend yield of 1.7%.
Current consensus EPS estimate suggests the PER is 33.9.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 6.00 cents and EPS of 11.50 cents.
At the last closing share price the estimated dividend yield is 1.81%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 28.87.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 12.5, implying annual growth of 27.6%.
Current consensus DPS estimate is 8.5, implying a prospective dividend yield of 2.6%.
Current consensus EPS estimate suggests the PER is 26.6.

Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

FFX    FIREFINCH LIMITED

Gold & Silver – Overnight Price: $0.20

Canaccord Genuity rates ((FFX)) as No Rating (-1) –

The Economic Community of West African States have lifted sanctions on Mali after the transitional government agreed to the restoration of civilian rules, democratic election and constitutional reform by March 2024.

This means the reopening of borders for the land-locked Mali, which had been inhibiting the flow of mining equipment.

Canaccord Genuity keeps Firefinch Under Review after news last weeks the sanctions had caused it to miss June-quarter production forecasts at Morila.

This report was published on July 7, 2022.

Current Price is $0.20. Target price not assessed.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

FPH    FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

Medical Equipment & Devices – Overnight Price: $19.37

JP Morgan rates ((FPH)) as Neutral (3) –

After minor upgrades to earnings forecasts due to exchange rate movements, JP Morgan raises its price target for Fisher & Paykel Healthcare to NZ$22.50 from NZ$22.00. The Neutral rating is retained.

This report was published on July 7, 2022.

Current Price is $19.37. Target price not assessed.
Current consensus price target is $21.10, suggesting upside of 11.2%(ex-dividends)
The company's fiscal year ends in March.

Forecast for FY23:

JP Morgan forecasts a full year FY23 dividend of 37.47 cents and EPS of 47.78 cents.
At the last closing share price the estimated dividend yield is 1.93%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 40.54.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 44.2, implying annual growth of N/A.
Current consensus DPS estimate is 31.3, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 42.9.

Forecast for FY24:

JP Morgan forecasts a full year FY24 dividend of 39.34 cents and EPS of 66.51 cents.
At the last closing share price the estimated dividend yield is 2.03%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 29.12.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 53.3, implying annual growth of 20.6%.
Current consensus DPS estimate is 33.6, implying a prospective dividend yield of 1.8%.
Current consensus EPS estimate suggests the PER is 35.6.

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

HLS    HEALIUS LIMITED

Healthcare services – Overnight Price: $3.70

Goldman Sachs rates ((HLS)) as Neutral (3) –

Goldman Sachs notes recent investment into the applications of AI into radiology mean the technology is approaching commercialisation and revenue generation. 

While the AI algorithms improve efficiency and accuracy of diagnosis, the broker notes the technology can also provide productivity gains that could help mitigate a shortage of radiologists in the near-term.

For Healius, the broker maintains a Neutral rating and target price of $4.20.

This report was published on July 7, 2022.

Target price is $4.20 Current Price is $3.70 Difference: $0.5
If HLS meets the Goldman Sachs target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $4.34, suggesting upside of 16.4%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Goldman Sachs forecasts a full year FY22 dividend of 30.20 cents and EPS of 54.80 cents.
At the last closing share price the estimated dividend yield is 8.16%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.75.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 52.0, implying annual growth of 519.0%.
Current consensus DPS estimate is 15.6, implying a prospective dividend yield of 4.2%.
Current consensus EPS estimate suggests the PER is 7.2.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 13.40 cents and EPS of 23.20 cents.
At the last closing share price the estimated dividend yield is 3.62%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.95.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 22.9, implying annual growth of -56.0%.
Current consensus DPS estimate is 14.0, implying a prospective dividend yield of 3.8%.
Current consensus EPS estimate suggests the PER is 16.3.

Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

HUB    HUB24 LIMITED

Wealth Management & Investments – Overnight Price: $23.22

Jarden rates ((HUB)) as Neutral (3) –

Jarden has made negative mark to market adjustments across its wealth platforms and asset management coverage, accounting for recent weakness in equity and bonds markets. 

Across wealth managers, the broker highlighted while weaker markets weighted on funds under administration across the sector it does see better value outside of Hub24. 

The Neutral rating is retained and the target price decreases to $23.85 from $24.35.

This report was published on July 6, 2022.

Target price is $23.85 Current Price is $23.22 Difference: $0.63
If HUB meets the Jarden target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $30.78, suggesting upside of 36.1%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 19.80 cents and EPS of 43.90 cents.
At the last closing share price the estimated dividend yield is 0.85%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 52.89.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 41.1, implying annual growth of 223.1%.
Current consensus DPS estimate is 17.7, implying a prospective dividend yield of 0.8%.
Current consensus EPS estimate suggests the PER is 55.0.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 25.60 cents and EPS of 57.70 cents.
At the last closing share price the estimated dividend yield is 1.10%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 40.24.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 59.3, implying annual growth of 44.3%.
Current consensus DPS estimate is 25.2, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 38.1.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

HVN    HARVEY NORMAN HOLDINGS LIMITED

Consumer Electronics – Overnight Price: $3.95

Jarden rates ((HVN)) as Upgrade to Neutral from Underweight (3) –

Jarden lowers forecasts for stocks under its coverage in the Discretionary Retail sector to reflect a weaker outlook, though feels risks are becoming more balanced.

The broker lifts its cost-of-doing-business forecasts across its coverage, which lowers its EPS forecasts for FY23 and FY24 by -3-4% for household goods and -15-19% for fashion/recreation.

Despite an overall Underweight rating for household goods names, the broker upgrades its rating for Harvey Norman to Neutral from Underweight following a recent share price underperformance. It's felt property and Asian exposures lend resilience.

The target price falls to $4.30 from $5.50.

This report was published on July 8, 2022.

Target price is $4.30 Current Price is $3.95 Difference: $0.35
If HVN meets the Jarden target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $4.62, suggesting upside of 18.5%(ex-dividends)

Forecast for FY22:

Current consensus EPS estimate is 50.5, implying annual growth of -25.2%.
Current consensus DPS estimate is 35.5, implying a prospective dividend yield of 9.1%.
Current consensus EPS estimate suggests the PER is 7.7.

Forecast for FY23:

Current consensus EPS estimate is 36.5, implying annual growth of -27.7%.
Current consensus DPS estimate is 28.5, implying a prospective dividend yield of 7.3%.
Current consensus EPS estimate suggests the PER is 10.7.

Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

IDX    INTEGRAL DIAGNOSTICS LIMITED

Medical Equipment & Devices – Overnight Price: $2.94

Goldman Sachs rates ((IDX)) as Buy (1) –

Goldman Sachs notes recent investment into the applications of AI into radiology mean the technology is approaching commercialisation and revenue generation. 

While the AI algorithms improve efficiency and accuracy of diagnosis, the broker notes the technology can also provide productivity gains that could help mitigate a shortage of radiologists in the near-term.

For Integral Diagnostics, the broker maintains a Buy rating and target price of $4.20, noting the Buy rating is attributed to factors outside AI. 

This report was published on July 7, 2022.

Target price is $4.20 Current Price is $2.94 Difference: $1.26
If IDX meets the Goldman Sachs target it will return approximately 43% (excluding dividends, fees and charges).
Current consensus price target is $4.26, suggesting upside of 46.9%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Goldman Sachs forecasts a full year FY22 dividend of 8.30 cents and EPS of 13.30 cents.
At the last closing share price the estimated dividend yield is 2.82%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 22.11.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 13.2, implying annual growth of -15.3%.
Current consensus DPS estimate is 9.1, implying a prospective dividend yield of 3.1%.
Current consensus EPS estimate suggests the PER is 22.0.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 11.50 cents and EPS of 18.00 cents.
At the last closing share price the estimated dividend yield is 3.91%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.33.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 20.0, implying annual growth of 51.5%.
Current consensus DPS estimate is 13.0, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 14.5.

Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

IFL    INSIGNIA FINANCIAL LIMITED

Wealth Management & Investments – Overnight Price: $2.79

Jarden rates ((IFL)) as Buy (1) –

Jarden has made negative mark to market adjustments across its wealth platforms and asset management coverage, accounting for recent weakness in equity and bonds markets. 

Across wealth managers, the broker highlighted while weaker markets weighted on funds under administration across the sector it expects net outflows across Insignia Financial's wealth management acquisitions to stabilise gradually. 

Insignia Financial remains the broker's sector pick. The Buy rating is retained and the target price decreases to $3.15 from $4.90.

This report was published on July 6, 2022.

Target price is $3.15 Current Price is $2.79 Difference: $0.36
If IFL meets the Jarden target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $4.89, suggesting upside of 76.4%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 21.90 cents and EPS of 33.70 cents.
At the last closing share price the estimated dividend yield is 7.85%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.28.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 36.5, implying annual growth of N/A.
Current consensus DPS estimate is 24.7, implying a prospective dividend yield of 8.9%.
Current consensus EPS estimate suggests the PER is 7.6.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 19.20 cents and EPS of 29.50 cents.
At the last closing share price the estimated dividend yield is 6.88%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.46.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 39.6, implying annual growth of 8.5%.
Current consensus DPS estimate is 27.1, implying a prospective dividend yield of 9.8%.
Current consensus EPS estimate suggests the PER is 7.0.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

JAN    JANISON EDUCATION GROUP LIMITED

Education & Tuition – Overnight Price: $0.46

Bell Potter rates ((JAN)) as Buy (1) –

Janison Education's downgraded revenue guidance in its FY22 trading update, forecasting a rise of 20%, down from 45% previously, due to a delay in contract signings due to covid.

On the upside, Bell Potter notes the company has reset its cost base and expects to be cash flow positive in FY23.

FY22, FY23 and FY24 revenue forecasts fall -10%, -22% and -22%.

Bell Potter expects contract signings will continue to be delayed and considers the company's FY25 revenue horizon to be ambitious.

Buy rating retained. Target price falls to 70c from 90c.

This report was published on July 11, 2022.

Target price is $0.70 Current Price is $0.46 Difference: $0.24
If JAN meets the Bell Potter target it will return approximately 52% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 3.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 13.53.

Forecast for FY23:

Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 2.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 19.17.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

JHG    JANUS HENDERSON GROUP PLC

Wealth Management & Investments – Overnight Price: $34.67

Jarden rates ((JHG)) as Underweight (4) –

Jarden has made negative mark to market adjustments across its wealth platforms and asset management coverage, accounting for recent weakness in equity and bonds markets. 

Across asset managers, the broker highlighted weaker markets weighted on funds under management and cost pressures appear to assist. 

For Janus Henderson, the broker retains an Underweight rating and the target price decreases to $24.00 from $38.05.

This report was published on July 6, 2022.

Target price is $24.00 Current Price is $34.67 Difference: minus $10.67 (current price is over target).
If JHG meets the Jarden target it will return approximately minus 31% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $45.25, suggesting upside of 32.2%(ex-dividends)
The company's fiscal year ends in December.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 215.38 cents and EPS of 324.45 cents.
At the last closing share price the estimated dividend yield is 6.21%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.69.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 496.2, implying annual growth of N/A.
Current consensus DPS estimate is 231.6, implying a prospective dividend yield of 6.8%.
Current consensus EPS estimate suggests the PER is 6.9.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 215.38 cents and EPS of 310.65 cents.
At the last closing share price the estimated dividend yield is 6.21%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.16.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 501.1, implying annual growth of 1.0%.
Current consensus DPS estimate is 281.2, implying a prospective dividend yield of 8.2%.
Current consensus EPS estimate suggests the PER is 6.8.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

MFG    MAGELLAN FINANCIAL GROUP LIMITED

Wealth Management & Investments – Overnight Price: $11.90

Jarden rates ((MFG)) as Underweight (4) –

Jarden has made negative mark to market adjustments across its wealth platforms and asset management coverage, accounting for recent weakness in equity and bonds markets. 

Across asset managers, the broker highlighted weaker markets weighted on funds under management and cost pressures appear to assist. 

For Magellan Financial, the broker retains an Underweight rating and the target price decreases to $10.10 from $12.70.

This report was published on July 6, 2022.

Target price is $10.10 Current Price is $11.90 Difference: minus $1.8 (current price is over target).
If MFG meets the Jarden target it will return approximately minus 15% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $12.17, suggesting upside of 2.7%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 193.00 cents and EPS of 228.00 cents.
At the last closing share price the estimated dividend yield is 16.22%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 5.22.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 216.9, implying annual growth of 50.0%.
Current consensus DPS estimate is 185.5, implying a prospective dividend yield of 15.7%.
Current consensus EPS estimate suggests the PER is 5.5.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 113.00 cents and EPS of 129.00 cents.
At the last closing share price the estimated dividend yield is 9.50%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.22.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 124.9, implying annual growth of -42.4%.
Current consensus DPS estimate is 110.1, implying a prospective dividend yield of 9.3%.
Current consensus EPS estimate suggests the PER is 9.5.

Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

MMI    METRO MINING LIMITED

Coal – Overnight Price: $0.02

Shaw and Partners rates ((MMI)) as Buy (1) –

Shaw and Partners expects Metro Mining will be a beneficiary of a tightening bauxite market over the next decade, with the broker highlighting Australian exporters will be well placed to benefit from increased demand and potentially higher prices. 

The company has recently announced intentions to increase the production capacity of its Bauxite Hills operations to 7m tonnes from a current 4m tonnes, coinciding with a likely increase in imports by China in coming years.

The Buy rating and target price of $0.08 are retained.

This report was published on July 8, 2022.

Target price is $0.08 Current Price is $0.02 Difference: $0.06
If MMI meets the Shaw and Partners target it will return approximately 300% (excluding dividends, fees and charges).
The company's fiscal year ends in December.

Forecast for FY22:

Shaw and Partners forecasts a full year FY22 dividend of 0.00 cents and EPS of 0.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.67.

Forecast for FY23:

Shaw and Partners forecasts a full year FY23 dividend of 0.00 cents and EPS of 0.90 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 2.22.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

NWL    NETWEALTH GROUP LIMITED

Wealth Management & Investments – Overnight Price: $12.63

Jarden rates ((NWL)) as Neutral (3) –

Jarden has made negative mark to market adjustments across its wealth platforms and asset management coverage, accounting for recent weakness in equity and bonds markets. 

Across wealth managers, the broker highlighted while weaker markets weighted on funds under administration across the sector it does see better value outside of Netwealth Group. 

The Neutral rating is retained and the target price decreases to $13.15 from $14.45.

This report was published on July 6, 2022.

Target price is $13.15 Current Price is $12.63 Difference: $0.52
If NWL meets the Jarden target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $15.67, suggesting upside of 26.9%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 19.90 cents and EPS of 22.70 cents.
At the last closing share price the estimated dividend yield is 1.58%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 55.64.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 23.6, implying annual growth of 4.7%.
Current consensus DPS estimate is 19.9, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 52.3.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 25.70 cents and EPS of 29.70 cents.
At the last closing share price the estimated dividend yield is 2.03%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 42.53.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 30.6, implying annual growth of 29.7%.
Current consensus DPS estimate is 25.2, implying a prospective dividend yield of 2.0%.
Current consensus EPS estimate suggests the PER is 40.4.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

OKU    OKLO RESOURCES LIMITED

Gold & Silver – Overnight Price: $0.14

Canaccord Genuity rates ((OKU)) as Buy (1) –

The Economic Community of West African States have lifted sanctions on Mali after the transitional government agreed to the restoration of civilian rules, democratic election and constitutional reform by March 2024.

This means the reopening of borders for the land-locked Mali, which had been inhibiting the flow of mining equipment.

Canaccord Genuity notes Oklo Resources is soon to be acquired by B2Gold, was largely unaffected by the sanctions.

Speculative Buy rating and 17c target price retained.

This report was published on July 6, 2022.

Target price is $0.17 Current Price is $0.14 Difference: $0.03
If OKU meets the Canaccord Genuity target it will return approximately 21% (excluding dividends, fees and charges).

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

PDL    PENDAL GROUP LIMITED

Wealth Management & Investments – Overnight Price: $4.37

Jarden rates ((PDL)) as Buy (1) –

Jarden has made negative mark to market adjustments across its wealth platforms and asset management coverage, accounting for recent weakness in equity and bonds markets. 

Across asset managers, the broker highlighted weaker markets weighted on funds under management and cost pressures appear to assist. For Pendal Group, the broker expects fund performance improvement should improve flows in the near term.

Pendal Group remains the broker's sector pick. The Buy rating is retained and the target price decreases to $4.70 from $6.50.

This report was published on July 6, 2022.

Target price is $4.70 Current Price is $4.37 Difference: $0.33
If PDL meets the Jarden target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $5.42, suggesting upside of 25.5%(ex-dividends)
The company's fiscal year ends in September.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 44.30 cents and EPS of 47.30 cents.
At the last closing share price the estimated dividend yield is 10.14%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.24.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 51.8, implying annual growth of -0.3%.
Current consensus DPS estimate is 45.8, implying a prospective dividend yield of 10.6%.
Current consensus EPS estimate suggests the PER is 8.3.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 32.50 cents and EPS of 36.20 cents.
At the last closing share price the estimated dividend yield is 7.44%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.07.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 44.3, implying annual growth of -14.5%.
Current consensus DPS estimate is 39.3, implying a prospective dividend yield of 9.1%.
Current consensus EPS estimate suggests the PER is 9.8.

Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

PME    PRO MEDICUS LIMITED

Medical Equipment & Devices – Overnight Price: $47.52

Goldman Sachs rates ((PME)) as Upgrade to Neutral from Sell (3) –

Goldman Sachs notes recent investment into the applications of AI into radiology mean the technology is approaching commercialisation and revenue generation. 

Within its coverage, Goldman Sachs finds Pro Medicus best placed to benefit from wider commercialisation of AI technology, with the company working with academic institutions and third party vendors to develop AI for radiology, to be hosted through its Visage suite.

The company is already generating revenue from its breast density AI algorithm and the broker expects AI will be 3-9% accretive to Pro Medicus' revenue between FY24-26. 

The broker notes the stock has underperformed the ASX 200 by -16% since it downgraded to Sell rating on the company in September, but the now improved risk-reward balance sees the rating upgraded to Neutral from Sell. The target price increased 9% to $42.60 from $39.10.

This report was published on July 7, 2022.

Target price is $42.60 Current Price is $47.52 Difference: minus $4.92 (current price is over target).
If PME meets the Goldman Sachs target it will return approximately minus 10% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

PPT    PERPETUAL LIMITED

Wealth Management & Investments – Overnight Price: $29.19

Jarden rates ((PPT)) as Underweight (4) –

Jarden has made negative mark to market adjustments across its wealth platforms and asset management coverage, accounting for recent weakness in equity and bonds markets. 

Across asset managers, the broker highlighted weaker markets weighted on funds under management and cost pressures appear to assist. 

For Perpetual, the broker retains an Underweight rating and the target price decreases to $24.45 from $31.95.

This report was published on July 6, 2022.

Target price is $24.45 Current Price is $29.19 Difference: minus $4.74 (current price is over target).
If PPT meets the Jarden target it will return approximately minus 16% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $37.26, suggesting upside of 27.9%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 204.20 cents and EPS of 245.00 cents.
At the last closing share price the estimated dividend yield is 7.00%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.91.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 261.6, implying annual growth of 93.8%.
Current consensus DPS estimate is 216.6, implying a prospective dividend yield of 7.4%.
Current consensus EPS estimate suggests the PER is 11.1.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 167.30 cents and EPS of 194.00 cents.
At the last closing share price the estimated dividend yield is 5.73%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.05.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 267.4, implying annual growth of 2.2%.
Current consensus DPS estimate is 218.0, implying a prospective dividend yield of 7.5%.
Current consensus EPS estimate suggests the PER is 10.9.

Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

PTM    PLATINUM ASSET MANAGEMENT LIMITED

Wealth Management & Investments – Overnight Price: $1.78

Jarden rates ((PTM)) as Underweight (4) –

Jarden has made negative mark to market adjustments across its wealth platforms and asset management coverage, accounting for recent weakness in equity and bonds markets. 

Across asset managers, the broker highlighted weaker markets weighted on funds under management and cost pressures appear to assist. 

For Platinum Asset Management, the broker retains an Underweight rating and the target price decreases to $1.75 from $2.00.

This report was published on July 6, 2022.

Target price is $1.75 Current Price is $1.78 Difference: minus $0.03 (current price is over target).
If PTM meets the Jarden target it will return approximately minus 2% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $2.14, suggesting upside of 22.5%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 17.60 cents and EPS of 17.70 cents.
At the last closing share price the estimated dividend yield is 9.89%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.06.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 20.8, implying annual growth of -26.2%.
Current consensus DPS estimate is 19.7, implying a prospective dividend yield of 11.3%.
Current consensus EPS estimate suggests the PER is 8.4.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 14.30 cents and EPS of 16.70 cents.
At the last closing share price the estimated dividend yield is 8.03%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.66.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 18.0, implying annual growth of -13.5%.
Current consensus DPS estimate is 17.3, implying a prospective dividend yield of 9.9%.
Current consensus EPS estimate suggests the PER is 9.7.

Market Sentiment: -0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

REA    REA GROUP LIMITED

Real Estate – Overnight Price: $122.50

Goldman Sachs rates ((REA)) as Buy (1) –

Goldman Sachs examines the medium-term earnings outlook for Australian classifieds post covid, and spies valuation support for property classifieds.

The broker says fundamentals are positive for real-estate classifieds and expects budgets will rise at the expense of commissions and cites general undermonetisation of lead generation.

Goldman Sachs notes a gloomy property outlook is pressuring share prices over earnings but expects declining off-market listings and rental recovery will support listings into the medium term.

The broker is particularly fond of REA Group and adds it to the Conviction list, forecasting 34% to the current target price over the medium term, expecting strong yield upside, emerging valuation support and a reasonable macro environment.

EPS forecasts rise 1% to 313c in FY22 and 345c in FY23.

Buy rating retained. Target price slips to $164 from $167 on June 7.

This report was published on July 11, 2022.

Target price is $164.00 Current Price is $122.50 Difference: $41.5
If REA meets the Goldman Sachs target it will return approximately 34% (excluding dividends, fees and charges).
Current consensus price target is $133.43, suggesting upside of 11.1%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Goldman Sachs forecasts a full year FY22 dividend of 156.00 cents and EPS of 313.00 cents.
At the last closing share price the estimated dividend yield is 1.27%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 39.14.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 310.4, implying annual growth of 26.9%.
Current consensus DPS estimate is 164.7, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 38.7.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 190.00 cents and EPS of 345.00 cents.
At the last closing share price the estimated dividend yield is 1.55%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 35.51.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 349.2, implying annual growth of 12.5%.
Current consensus DPS estimate is 191.2, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 34.4.

Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

RMC    RESIMAC GROUP LIMITED

Banks – Overnight Price: $1.19

Bell Potter rates ((RMC)) as Buy (1) –

Bell Potter cuts Resimac Group's target price to $2.15 from its $3.30 March level, when it ceased coverage before transferring to a new analyst.

The broker notes the company is small but profitable and paying dividends, and the company has posted a four-year compound annual growth rate in net interest income of 33%.

But risks are rising along with interest rates and toppy property prices. The broker notes loan valuation ratios are low and lenders' mortgage insurance applies to prime loans and labour shortages continue.

But the broker doubts a recession is on the cards and considers the derating from $2.73 in February may be overrated (the share price is trading at just 4.7 times 2022 prospective earnings) given the level of provisioning required for such a price would be "extreme and unlikely".

Speculative Buy rating retained.

This report was published on July 11, 2022.

Target price is $2.15 Current Price is $1.19 Difference: $0.96
If RMC meets the Bell Potter target it will return approximately 81% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY22:

Bell Potter forecasts a full year FY22 dividend of 7.00 cents and EPS of 25.30 cents.
At the last closing share price the estimated dividend yield is 5.88%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 4.70.

Forecast for FY23:

Bell Potter forecasts a full year FY23 dividend of 8.00 cents and EPS of 23.50 cents.
At the last closing share price the estimated dividend yield is 6.72%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 5.06.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

RMD    RESMED INC

Medical Equipment & Devices – Overnight Price: $32.05

Jarden rates ((RMD)) as Overweight (2) –

Jarden previews ResMed's fourth quarter results, due to be released in early August, upgrading its net profit forecasts for not only the fourth quarter, but also FY23 and FY24, by 5.5%, 1.6% and 1.6% respectively, accounting for expected success from the company's Card to Cloud devices.

The upgrade brings Jarden's expected fourth quarter profit from ResMed to $217.4m. The broker highlights while semiconductor chip supply constraint has limited the company's ability to take advantage of the Philips recall, the workaround Card to Cloud CPAP appears to be resonating in the US.

The Overweight rating is retained and the target price decreases to $35.47 from $35.93.

This report was published on July 7, 2022.

Target price is $35.47 Current Price is $32.05 Difference: $3.42
If RMD meets the Jarden target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $35.76, suggesting upside of 12.9%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 231.95 cents and EPS of 798.56 cents.
At the last closing share price the estimated dividend yield is 7.24%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 4.01.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 83.9, implying annual growth of N/A.
Current consensus DPS estimate is 24.6, implying a prospective dividend yield of 0.8%.
Current consensus EPS estimate suggests the PER is 37.7.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 231.95 cents and EPS of 958.58 cents.
At the last closing share price the estimated dividend yield is 7.24%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 3.34.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 101.6, implying annual growth of 21.1%.
Current consensus DPS estimate is 26.0, implying a prospective dividend yield of 0.8%.
Current consensus EPS estimate suggests the PER is 31.2.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

RSG    RESOLUTE MINING LIMITED

Gold & Silver – Overnight Price: $0.25

Canaccord Genuity rates ((RSG)) as Buy (1) –

The Economic Community of West African States have lifted sanctions on Mali after the transitional government agreed to the restoration of civilian rules, democratic election and constitutional reform by March 2024.

This means the reopening of borders for the land-locked Mali, which had been inhibiting the flow of mining equipment.

Cannacord Genuity retains a Speculative Buy rating and 65c target price for Resolute Mining.

This report was published on July 7, 2022.

Target price is $0.65 Current Price is $0.25 Difference: $0.4
If RSG meets the Canaccord Genuity target it will return approximately 160% (excluding dividends, fees and charges).

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

SBM    ST. BARBARA LIMITED

Gold & Silver – Overnight Price: $0.91

Shaw and Partners rates ((SBM)) as Initiation of coverage with Buy (1) –

Shaw and Partners initiates coverage of St. Barbara with a Buy rating and $1.80 target price.

The broker observes the company is a leading listed mid-tier Australian gold producer and is focusing on the Leonora province assets near the Gwalia mine, and is considering selling non-core assets such as Simberi and Atlantic.

Catalysts include expansion of the Leonora mines and reserves and the broker appreciates the modest debt of 5c a share, compared with net assets of 36c, and cash reserves to build out to FY25.

This report was published on July 11, 2022.

Target price is $1.80 Current Price is $0.91 Difference: $0.89
If SBM meets the Shaw and Partners target it will return approximately 98% (excluding dividends, fees and charges).
Current consensus price target is $1.26, suggesting upside of 38.7%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Shaw and Partners forecasts a full year FY22 dividend of 0.00 cents and EPS of 3.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 30.33.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 2.2, implying annual growth of N/A.
Current consensus DPS estimate is 0.5, implying a prospective dividend yield of 0.5%.
Current consensus EPS estimate suggests the PER is 41.4.

Forecast for FY23:

Shaw and Partners forecasts a full year FY23 dividend of 0.00 cents and EPS of 9.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.68.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 7.7, implying annual growth of 250.0%.
Current consensus DPS estimate is 1.5, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 11.8.

Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

SHL    SONIC HEALTHCARE LIMITED

Healthcare services – Overnight Price: $33.30

Goldman Sachs rates ((SHL)) as Neutral (3) –

Goldman Sachs notes recent investment into the applications of AI into radiology mean the technology is approaching commercialisation and revenue generation. 

While the AI algorithms improve efficiency and accuracy of diagnosis, the broker notes the technology can also provide productivity gains that could help mitigate a shortage of radiologists in the near-term.

For Sonic Healthcare, the broker maintains a Neutral rating and target price of $36.40.

This report was published on July 7, 2022.

Target price is $36.40 Current Price is $33.30 Difference: $3.1
If SHL meets the Goldman Sachs target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $37.96, suggesting upside of 12.7%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY22:

Goldman Sachs forecasts a full year FY22 dividend of 73.50 cents and EPS of 293.00 cents.
At the last closing share price the estimated dividend yield is 2.21%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.37.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 307.9, implying annual growth of 11.8%.
Current consensus DPS estimate is 99.4, implying a prospective dividend yield of 3.0%.
Current consensus EPS estimate suggests the PER is 10.9.

Forecast for FY23:

Goldman Sachs forecasts a full year FY23 dividend of 124.00 cents and EPS of 165.00 cents.
At the last closing share price the estimated dividend yield is 3.72%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.18.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 178.8, implying annual growth of -41.9%.
Current consensus DPS estimate is 107.6, implying a prospective dividend yield of 3.2%.
Current consensus EPS estimate suggests the PER is 18.8.

Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

WAF    WEST AFRICAN RESOURCES LIMITED

Gold & Silver – Overnight Price: $1.18

Shaw and Partners rates ((WAF)) as Buy (1) –

West African Resources has announced extensive gold mineralisation at MV3 prospect zones in Burkina Faso, 6km from their Sanbrado mine.

Shaw and Partners notes drilling continues with potential to expand the Sanbrado mine life, and the company has confirmed that the feasibility study for the Kiaka Gold project is on track.

Buy rating and $1.47 target price retained.

This report was published on July 11, 2022.

Target price is $1.47 Current Price is $1.18 Difference: $0.29
If WAF meets the Shaw and Partners target it will return approximately 25% (excluding dividends, fees and charges).
The company's fiscal year ends in December.

Forecast for FY22:

Shaw and Partners forecasts a full year FY22 dividend of 0.00 cents and EPS of 20.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 5.87.

Forecast for FY23:

Shaw and Partners forecasts a full year FY23 dividend of 0.00 cents and EPS of 15.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.87.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface. This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.

As part of emerging new trends overseas, The Australian Broker Call *Extra* Edition also includes providers of sponsored research. Readers should bear in mind, sponsored research, while not necessarily of lower quality, has the embedded complication that the company that is the subject of the research has paid for this research. Providers of sponsored research that can potentially be included in this Report are Breakaway Research, Edison Investment Research, Independent Investment Research, NDF Research, Pitt Street Research, and TMT Analytics.

Decisions about inclusions in this Report are made independently of the providers of stock market research and at full discretion of the team of journalists responsible for content at FNArena. Inclusion does not equal endorsement, in any way, shape or form. This Report is provided for informational purposes only.

Share on FacebookTweet about this on TwitterShare on LinkedIn

Click to view our Glossary of Financial Terms

CHARTS

ACL ADH AMP ASX BCI CHN DHG FFX FPH HLS HUB HVN IDX IFL JAN JHG MFG MMI NEC NWL OKU PDL PME PPT PTM REA RMC RMD RSG SBM SHL WAF

For more info SHARE ANALYSIS: ACL - AUSTRALIAN CLINICAL LABS LIMITED

For more info SHARE ANALYSIS: ADH - ADAIRS LIMITED

For more info SHARE ANALYSIS: AMP - AMP LIMITED

For more info SHARE ANALYSIS: ASX - ASX LIMITED

For more info SHARE ANALYSIS: BCI - BCI MINERALS LIMITED

For more info SHARE ANALYSIS: CHN - CHALICE MINING LIMITED

For more info SHARE ANALYSIS: DHG - DOMAIN HOLDINGS AUSTRALIA LIMITED

For more info SHARE ANALYSIS: FFX - FIREFINCH LIMITED

For more info SHARE ANALYSIS: HLS - HEALIUS LIMITED

For more info SHARE ANALYSIS: HUB - HUB24 LIMITED

For more info SHARE ANALYSIS: HVN - HARVEY NORMAN HOLDINGS LIMITED

For more info SHARE ANALYSIS: IDX - INTEGRAL DIAGNOSTICS LIMITED

For more info SHARE ANALYSIS: IFL - INSIGNIA FINANCIAL LIMITED

For more info SHARE ANALYSIS: JAN - JANISON EDUCATION GROUP LIMITED

For more info SHARE ANALYSIS: JHG - JANUS HENDERSON GROUP PLC

For more info SHARE ANALYSIS: MFG - MAGELLAN FINANCIAL GROUP LIMITED

For more info SHARE ANALYSIS: MMI - METRO MINING LIMITED

For more info SHARE ANALYSIS: NEC - NINE ENTERTAINMENT CO. HOLDINGS LIMITED

For more info SHARE ANALYSIS: NWL - NETWEALTH GROUP LIMITED

For more info SHARE ANALYSIS: OKU - OKLO RESOURCES LIMITED

For more info SHARE ANALYSIS: PDL - PENDAL GROUP LIMITED

For more info SHARE ANALYSIS: PME - PRO MEDICUS LIMITED

For more info SHARE ANALYSIS: PPT - PERPETUAL LIMITED

For more info SHARE ANALYSIS: PTM - PLATINUM ASSET MANAGEMENT LIMITED

For more info SHARE ANALYSIS: REA - REA GROUP LIMITED

For more info SHARE ANALYSIS: RMC - RESIMAC GROUP LIMITED

For more info SHARE ANALYSIS: RMD - RESMED INC

For more info SHARE ANALYSIS: RSG - RESOLUTE MINING LIMITED

For more info SHARE ANALYSIS: SBM - ST. BARBARA LIMITED

For more info SHARE ANALYSIS: SHL - SONIC HEALTHCARE LIMITED

For more info SHARE ANALYSIS: WAF - WEST AFRICAN RESOURCES LIMITED